The humoral immune response to the inactivated influenzaA (H1N1) 2009 monovalent vaccine in patients with Type2 diabetes mellitus in Korea

J. S. Nam, A. R. Kim, J. C. Yoon, Y. Byun, S. A. Kim, K. R. Kim, S. Cho, B. L. Seong, C. W. Ahn, J. M. Lee

Research output: Contribution to journalArticle

14 Citations (Scopus)


Aims We evaluated the antibody response to a single-dose adjuvanted, inactivated, pandemic H1N1 influenza vaccination in patients with diabetes and assessed factors associated with the failure to induce antibody responses. Methods Eighty-two patients with Type2 diabetes were vaccinated and antibody responses were determined with haemagglutination inhibition assay and anti-haemagglutinin antibody ELISA. Results Among 70 antibody-negative patients at baseline, 34 (48.6%) achieved seroconversion; 28 (60.9%) in the young adults group and six (25%) in the elderly group acquired H1N1-specific antibodies. Patients in the older age range or with longer duration of diabetes had a lower seroconversion rate. Conclusions Our data show low cross-reactive antibody carrying rate and low seroconversion rate in patients with diabetes. Until larger-scale, case-controlled trials become available, older patients and patients with a longer duration of diabetes should be considered for the two-dose vaccination or have antibody titres measured after the first vaccination.

Original languageEnglish
Pages (from-to)815-817
Number of pages3
JournalDiabetic Medicine
Issue number7
Publication statusPublished - 2011 Jul 1


All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this